C

바이오니아

064550KOSDAQ의료용품 및 기타 의약 관련제품 제조업

42.7 / 100

Reference Date: 2026-06-10

Financial Score11.5 / 40
News Sentiment19.2 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 23.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

BioNia is a biopharmaceutical company specializing in developing solutions for disease diagnosis, treatment, and prevention based on core biotechnology, with key businesses in life science research products, molecular diagnostics, probiotics, and RNAi-based drug development. Over 33 years, it has accumulated advanced genetic technologies, supplying PCR equipment, molecular diagnostic kits, and expanding into new areas like synthetic biology bioprinting and RNA-based cosmetics.

Number of Employees

362people

Average Salary

52.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
115.22Industry Average 19.190.0Point

6.0x industry avg (risky)

PBR
0.87Industry Average 1.305.5Point

Lower than industry avg (good)

ROE
0.75Industry Average -4.893.5Point

Well below industry avg

Debt Ratio
33.85Industry Average 6.860.0Point

4.9x industry avg (risky)

Trend 2023~20252.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲12.0% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼790.5% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.5% (improving, 3yr)

Detailed News Sentiment

8 totalPositive 6Neutral 2Negative 0Average Sentiment Score 76.9

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 7,620Won52-week high 16,53052-week low 7,620
1-month return0.0Point

1m -23.26% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral분기보고서 (2026.03)2026-05-15